ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
128.957,09
2,64%
S&P 500
5.638,94
2,13%
US Dollar vs BRL
5,7456
0,00%
Bitcoin
82.561,67
-2,12%
Brent Oil
70,765
0,68%
As Melhores Corretoras Online
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Vir Biotechnology Inc (VIR)

  7. Vir Biotechnology Inc (VIR) Notícias

VIR

Vir Biotechnology (VIR)

Vir Biotechnology Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:VIR
DataHoraFonteTítuloCódigoCompanhia
27/02/202514:39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIRVir Biotechnology Inc
27/02/202508:01Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:VIRVir Biotechnology Inc
26/02/202518:23Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VIRVir Biotechnology Inc
26/02/202518:17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRVir Biotechnology Inc
26/02/202518:05Business WireVir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial ResultsNASDAQ:VIRVir Biotechnology Inc
19/02/202518:05Business WireVir Biotechnology to Participate in TD Cowen 45th Annual Health Care ConferenceNASDAQ:VIRVir Biotechnology Inc
12/02/202518:05Business WireVir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025NASDAQ:VIRVir Biotechnology Inc
08/01/202509:45Business WireVir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPCNASDAQ:VIRVir Biotechnology Inc
18/12/202411:30Business WireVir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:VIRVir Biotechnology Inc
12/12/202418:05Business WireVir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis DeltaNASDAQ:VIRVir Biotechnology Inc
26/11/202411:30Business WireVir Biotechnology to Host Virtual Investor Event on PRO-XTEN™ Masked T-Cell Engager ProgramsNASDAQ:VIRVir Biotechnology Inc
25/11/202411:30Business WireVir Biotechnology to Participate in the 7th Annual Evercore ISI HealthCONx ConferenceNASDAQ:VIRVir Biotechnology Inc
18/11/202423:15Business WireVir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational ProgramNASDAQ:VIRVir Biotechnology Inc
18/11/202418:05Business WireVir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines AgencyNASDAQ:VIRVir Biotechnology Inc
15/11/202413:00Business WireVir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver MeetingNASDAQ:VIRVir Biotechnology Inc
04/11/202418:09Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VIRVir Biotechnology Inc
31/10/202417:05Business WireVir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:VIRVir Biotechnology Inc
17/10/202417:30Business WireVir Biotechnology to Provide Business Update and Report Third Quarter 2024 Financial Results on October 31, 2024NASDAQ:VIRVir Biotechnology Inc
15/10/202409:16Business WireVir Biotechnology Announces Clinical Advances Across Hepatitis Delta and Hepatitis B Programs at AASLD’s The Liver Meeting® 2024NASDAQ:VIRVir Biotechnology Inc
03/10/202418:11Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:VIRVir Biotechnology Inc
03/10/202417:00Business WireVir Biotechnology to Participate in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual ConferenceNASDAQ:VIRVir Biotechnology Inc
10/09/202409:05Business WireVir Biotechnology Appoints Jason O’Byrne as Chief Financial OfficerNASDAQ:VIRVir Biotechnology Inc
09/09/202417:05Business WireVir Biotechnology Announces Closing of Exclusive Worldwide License Agreement With Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-Cell EngagersNASDAQ:VIRVir Biotechnology Inc
22/08/202409:05Business WireVir Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferenceNASDAQ:VIRVir Biotechnology Inc
01/08/202417:02Business WireVir Biotechnology Reports Second Quarter 2024 Financial Results and Announces Strategic Restructuring to Prioritize Clinical-Stage Pipeline OpportunitiesNASDAQ:VIRVir Biotechnology Inc
01/08/202417:01Business WireVir Biotechnology Acts on Expanded Strategy of Powering the Immune System Through Exclusive Worldwide License Agreement with Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-cell EngagersNASDAQ:VIRVir Biotechnology Inc
18/07/202417:05Business WireVir Biotechnology to Report Second Quarter 2024 Financial Results on August 1, 2024NASDAQ:VIRVir Biotechnology Inc
26/06/202409:05Business WireVir Biotechnology Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta InfectionNASDAQ:VIRVir Biotechnology Inc
05/06/202406:30Business WireTobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT Normalization in People Living with the Hepatitis Delta Virus After 12 and 24 Weeks of TreatmentNASDAQ:VIRVir Biotechnology Inc
29/05/202417:05Business WireVir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:VIRVir Biotechnology Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:VIR

Seu Histórico Recente

TG
4WF
Wharf Real Estate Invest...
TG
NC0
News
TG
8QQ
AbCellera Biologics
TG
R8M
South Bow
TG
AI7
Azz
COIN
GEMSSUSD
Gempire.io
COIN
MICROUSD
MICROMINES
TG
6IO
Inogen
TG
PI6
Pieris Pharmaceuticals
TSXV
N
Namaste Technologies
TSX
ORV
Orvana Minerals
TG
02FW
First Trust ExchangeTrad...
TG
QDFD
FlexShares ICAV
TG
SSGN
SSgA Active
TG
XNPD
CNP Assurances
TG
CAJK
Casino Guichard Perrachon
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados

Vá sem anúncios

Assine uma experiência sem anúncios

Sem anúncios

Experimente agora

Manter os anúncios